In C57BL/6 mice fed a high-fat diet, eight weeks of nicotinamide mononucleotide (NMN), a precursor in the NAD+ salvage pathway, lowered body weight and reduced liver fat on H&E and Oil Red O staining. Serum LDL, triglycerides, total cholesterol and fasting glucose fell while HDL rose. Mechanistically, hepatic PPAR-γ dropped and HNF4α and SHBG increased, a pattern the authors tie to improved lipid handling; palmitate-loaded HepG2 cells supported the signal.
The evidence here comes from mice and cultured cells, not people, and that distinction matters. NMN has become a popular supplement on the strength of NAD+ biology, yet human data remain thin: small trials show NMN raises blood NAD+ and may modestly aid muscle or insulin sensitivity in specific groups, but none has shown it reverses fatty liver or improves clinical liver outcomes. Mouse high-fat-diet models also tend to flatter interventions, since part of the benefit may simply reflect lower body weight rather than a liver-specific effect, and this design cannot separate the two. The network pharmacology and transcriptomic layers generate hypotheses about PPAR-γ and HNF4α but do not prove causality. Doses used in mice are also not directly translatable to human supplement servings. Editorially, this is confirmatory and incremental: it adds to a consistent preclinical literature on NAD+ precursors and steatosis. For adults with fatty liver, weight loss, diet quality and exercise remain the evidence-based tools; NMN deserves a randomized liver-fat trial before it earns a place in that conversation.